Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01694927

Acronym

MSC-SCI

Enrollment

Registered

2012-09-27

Start date

2012-01-31

Completion date

2014-06-30

Last updated

2013-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Keywords

Mesenchymal stem cell, Spinal cord injury

Brief summary

The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Interventions

PROCEDUREAutologous Mesenchymal Stem Cells

Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 65 Years

Healthy volunteers

Inclusion criteria

* American Spinal Injury Association Impairment (ASIA) Scale A, B and C * Cervical (under C4), thoracic o lumbar spine lesion * Complete or Incomplete SCI * Platelet count over 100.000/ul

Exclusion criteria

* Acute SCI (less than 3 months) * Active infectious diseases * Pregnancy * Neurodegenerative diseases * Primary hematologic diseases * Coagulopathies * Hepatic dysfunction * Pregnancy

Design outcomes

Primary

Measure	Time frame
Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients	3 months

Secondary

Measure	Time frame	Description
Functional improvement in muscle strength	1 year	According to motor index score
Functional Improvement in sphincters control	1 year	—
Functional improvement in spasticity control	1 year	—

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026